The objective of this proposal is to characterize leukemia derived growth factor (LDGF), an autostimulatory growth factor which has been purified to homogeneity from murine T lymphoma cells where it is expressed constitutively. It is proposed that disregulation of this 12,000 MW glycoprotein growth factor leads to development of lymphoma in the thymus. A binding assay using radiolabeled LDGF will be developed to identify LDGF receptor on various target cells. The relationship of LDGF to normal lymphocyte physiology will be defined using thymocyte subpopulations and B lymphoblast lines. The role of LDGF in the induction of oncogene expression in T lymphomas and LDGF-responsive normal cells will be evaluated. The purification method developed provides sufficient quantities of protein for amino acid sequencing. This step will allow the synthesis of peptides for antibody preparation. Specific antibody will be used to develop a radioimmunoassay. Antibodies will test expression of the molecule in various cell populations. Antibody effect on LDGF-stimulated cell growth will be studied. Oligonucleotides will be prepared from a purified amino acid sequence to identify a cDNA clone encoding LDGF. Cells with high receptor numbers as determined in the binding studies will be used to purify the LDGF receptor protein. Characterization of LDGF and understanding of its the functions are important for two reasons: 1) there is little known about factors regulating about thymocyte development. LDGF may be such a factor; 2) the constitutive production of auto-stimulatory growth factors such as LDGF may be crucial to the independent growth of these cells. Therefore, investigation of this factor will add to knowledge of the growth and differentiation of normal lymphoid cells and may provide new approaches for early diagnosis and treatment of leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA012386-15
Application #
3163632
Study Section
Pathology B Study Section (PTHB)
Project Start
1979-09-01
Project End
1990-06-30
Budget Start
1988-12-01
Budget End
1990-06-30
Support Year
15
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Organized Research Units
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Uittenbogaart, C H; Law, W; Leenen, P J et al. (1998) Thymic dendritic cells are primary targets for the oncogenic virus SL3-3. J Virol 72:10118-25
Hays, E F; Bristol, G; McDougall, S (1990) Mechanisms of thymic lymphomagenesis by the retrovirus SL3-3. Cancer Res 50:5631S-5635S
Hays, E F; Bristol, G C; Lugo, J P et al. (1989) Progression to development of lymphoma in the thymus of AKR mice treated neonatally with SL 3-3 virus. Exp Hematol 17:1116-21
Hays, E F; Bristol, G C; McDougall, S et al. (1989) Development of lymphoma in the thymus of AKR mice treated with the lymphomagenic virus SL 3-3. Cancer Res 49:4225-30
Ueno, Y; Hays, E F; Hultin, L et al. (1989) Human thymocytes do not respond to interleukin-2 after removal of mature ""bright"" CD5 positive cells. Cell Immunol 124:239-51
Hays, E F; Kitada, S; Uittenbogaart, C H et al. (1988) Autocrine growth of murine lymphoma cells. J Natl Cancer Inst 80:116-21
MacLeod, C L; Minning, L; Gold, D P et al. (1986) Negative trans-regulation of T-cell antigen receptor/T3 complex mRNA expression in murine T-lymphoma somatic cell hybrids. Proc Natl Acad Sci U S A 83:6989-93
Hays, E F; Weinroth, S E; MacLeod, C L et al. (1986) Tumorigenicity of T lymphoma/T lymphoma hybrids and T lymphoma/normal cell hybrids. Int J Cancer 38:597-601
MacLeod, C L; Weinroth, S E; Streifinger, C et al. (1985) SL12 murine T-lymphoma: a new model for tumor cell heterogeneity. J Natl Cancer Inst 74:875-82
Kitada, S; Hays, E F (1985) Transferrin-like activity produced by murine malignant T-lymphoma cell lines. Cancer Res 45:3537-40

Showing the most recent 10 out of 13 publications